How real-world data is powering rare disease research Part 3. RWD advances in China
As real-world data (RWD) transforms the drug development landscape, its power to advance research is becoming tangible in the most challenging therapeutic arena—rare diseases. In this series, Parexel experts discuss current initiatives in North America, Europe and China that are accelerating the use of RWD in rare disease research.
Related Insights
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 1. RWD advances in North America
Apr 18, 2025
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025
Related Insights
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 1. RWD advances in North America
Apr 18, 2025
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025